ProfileGDS5678 / 1424980_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 81% 78% 83% 80% 82% 85% 84% 83% 82% 83% 82% 81% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4980279
GSM967853U87-EV human glioblastoma xenograft - Control 25.8241581
GSM967854U87-EV human glioblastoma xenograft - Control 35.3391278
GSM967855U87-EV human glioblastoma xenograft - Control 46.303283
GSM967856U87-EV human glioblastoma xenograft - Control 55.7593980
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7183282
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.1490385
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1400284
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0525383
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0302682
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0710683
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9398582
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7867581
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0010683